New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer

作者：Cang Shundong; Ma Yuehua; Liu Delong^*

来源：Journal of Hematology & Oncology, 2009, 2(1): 22.

DOI：10.1186/1756-8722-2-22

DNA methylation and histone acetylation are two well known epigenetic chromatin modifications. Epigenetic agents leading to DNA hypomethylation and histone hyperacetylation have been approved for treatment of hematological disorders. The first histone deacetylase inhibitor, vorinostat, has been licensed for cutaneous T cell lymphoma treatment. More than 11 new epigenetic agents are in various stages of clinical development for therapy of multiple cancer types. In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer.

• 出版日期2009-6-1
• 单位河南省人民医院